Mostrar el registro sencillo del documento
Caracterización de una variante de HLA en pacientes con reacción adversa cutánea a fármacos antiepilépticos
dc.rights.license | Atribución-NoComercial-SinDerivadas 4.0 Internacional |
dc.contributor.advisor | Uscátegui Daccarett, Angélica María |
dc.contributor.advisor | Yunis Londoño, Juan José |
dc.contributor.advisor | Caminos Pinzón, Jorge Eduardo |
dc.contributor.author | Rueda Rodríguez, María Camila |
dc.date.accessioned | 2021-01-26T14:52:55Z |
dc.date.available | 2021-01-26T14:52:55Z |
dc.date.issued | 2021-01-25 |
dc.identifier.uri | https://repositorio.unal.edu.co/handle/unal/78920 |
dc.description.abstract | The use of antiepileptic drugs (AEDs) is one of the most frequent causes of adverse reactions secondary to drugs, with variable severity and even death in 35% of cases. Genetic variants are considered a possible causal actor of hypersensitivity reactions, therefore genotyping of the HLA-A and B alleles has proven to be a cost-effective tool in the choice of management in patients with epilepsy. Objective: To determine the most frequent variant of HLA-A and B in patients with epilepsy who present an adverse skin reaction to antiepileptic drugs. Materials and methods: Ambispective case-control study. Convenience sampling, considering the diagnosis of epilepsy for cases and controls, and the diagnosis of adverse reaction to antiepileptic drugs for cases. HLA-A and B haplotypes will be typed from venous blood samples at Yunis Turbay y Cia SAS Medical Services laboratory, in order to compare the results of patients with and without adverse reaction to antiepileptic drugs. Expected results: Finding differences in the HLA-A and B typing of patients with epilepsy treated with AEDs who present cutaneous adverse reactions compared to those with the same diagnosis and treatment that do not present them. |
dc.description.abstract | El uso de fármacos antiepilépticos (FAE) es una de las causas más frecuentes de reacciones adversas secundarias a medicamentos, con severidad variable e incluso muerte en un 35% de los casos. Las variantes genéticas se consideran un posible actor causal de las reacciones de hipersensibilidad, por lo que la genotipificación de los alelos HLA-A y B ha resultado ser una herramienta costoefectiva en la elección de manejo en pacientes con epilepsia. Objetivo: Determinar la variante más frecuente del HLA-A y B en pacientes con epilepsia que presenten reacción adversa cutánea a fármacos antiepilépticos. Materiales y métodos: Estudio de casos y controles de corte ambispectivo. Muestreo por conveniencia, considerando el diagnóstico de epilepsia para casos y controles, y el diagnóstico de reacción adversa a medicamentos antiepilépticos para casos. A partir de muestras de sangre venosa se realizará la tipificación de los haplotipos del HLA-A y B en el laboratorio Servicios Médicos Yunis Turbay y Cia SAS, con el fin de comparar los resultados de pacientes con y sin reacción adversa a fármacos antiepilépticos. Resultados esperados: Encontrar diferencias en la tipificación de HLA-A y B de los pacientes con epilepsia tratados con FAE que presentan reacciones adversas cutáneas comparadas con aquellos con igual diagnóstico y tratamiento que no las presentan. |
dc.format.extent | 38 |
dc.format.mimetype | application/pdf |
dc.language.iso | spa |
dc.rights | Derechos reservados - Universidad Nacional de Colombia |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.subject.ddc | 610 - Medicina y salud::616 - Enfermedades |
dc.title | Caracterización de una variante de HLA en pacientes con reacción adversa cutánea a fármacos antiepilépticos |
dc.type | Otro |
dc.rights.spa | Acceso abierto |
dc.description.additional | Línea de Investigación: Epilepsia |
dc.type.driver | info:eu-repo/semantics/other |
dc.type.version | info:eu-repo/semantics/acceptedVersion |
dc.publisher.program | Bogotá - Medicina - Especialidad en Neuropediatría |
dc.contributor.researchgroup | NEUROPED-UNAL |
dc.description.degreelevel | Especialidades Médicas |
dc.publisher.branch | Universidad Nacional de Colombia - Sede Bogotá |
dc.relation.references | Organización Mundial de la Salud. Formulario Modelo de la OMS 2004. Formul Model la OMS 2004 [Internet]. 2004;543. Available from: http://apps.who.int/medicinedocs/en/d/Js5422s/4.4.html |
dc.relation.references | Godhwani N, Bahna SL. Antiepilepsy drugs and the immune system. Ann Allergy, Asthma Immunol. 2016;117(6):634–40. |
dc.relation.references | Zhao T, Li H, Wang T, Bahatibieke M, Jia L, Wang F. Association between HLA genotype and antiseizure medications ( ASMs ) - induced maculopapular eruption among epilepsy patients in Xinjiang , China. Epilepsy Res 2020;165:106391. |
dc.relation.references | An D-M, Wu X-T, Hu F-Y, Yan B, Stefan H, Zhou D. Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B*1502 in a Han Chinese population. Epilepsy Res. 2010;92(2–3):226–30. |
dc.relation.references | Brown S, Dauterive R. Anticonvulsant hypersensitivity syndrome to carbamazepine. Proc (Bayl Univ Med Cent). 2017;30(1):94–6. |
dc.relation.references | Chen Z, Liew D. Effects of a HLA-B * 15: 02 screening policy on antiepileptic drug use and severe skin reactions. Neurology. 2014; 83:1–8. |
dc.relation.references | Chaves Torres NM, Quijano Rodríguez JJ. Notificación de las reacciones adversas a los medicamentos antiepilépticos en Bogotá (Colombia, 2008-2012). Rev Cuba Neurol Neurocir. 2014;4(2):117–23. |
dc.relation.references | Tangamornsuksan W, Scholfield CN, Lohitnavy M. Association Between HLA genotypes and Oxcarbazepine-induced Cutaneous Adverse Drug Reactions : A Systematic Review and Meta- Analysis. J Pharm Pharm Sci. 2018;1–18. |
dc.relation.references | Usui T, Naisbitt DJ. Human leukocyte antigen and idiosyncratic adverse drug reactions. Drug Metab Pharmacokinet. 2016; http://dx.doi.org/10.1016/j.dmpk.2016.11.003 |
dc.relation.references | Genin E, Chen D-P, Hung S-I, Sekula P, Schumacher M, Chang P-Y, et al. HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. Pharmacogenomics J. 2014;14(3):281–8. |
dc.relation.references | Ramírez E, Bellin T, Tong HY, Borobia AM, de Abajo FJ, Lerma V, et al. Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS/TEN are different from those found for the same AED-induced DRESS in the Spanish population. Pharmacol Res. 2017;115:168–78. |
dc.relation.references | Ihtisham K, Ramanujam B, Srivastava S, Kumar N. Seizure : European Journal of Epilepsy Association of cutaneous adverse drug reactions due to antiepileptic drugs with HLA alleles in a North Indian population. Seizure Eur J Epilepsy. 2019; 66:99–103. |
dc.relation.references | Chen P, Lin J-J, Lu C-S, Ong C-T, Hsieh PF, Yang C-C, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med. 2011;364(12):1126–33. |
dc.relation.references | Choi H. Cost ‐ effectiveness of screening for HLA ‐ B * 1502 prior to initiation of carbamazepine in epilepsy patients of Asian ancestry in the United States. Epilepsia, 2019;(60):1472–81. |
dc.relation.references | Amstutz U, Shear NH, Rieder MJ, Hwang S, Fung V, Nakamura H, et al. Recommendations for HLA-B15:02 and HLA-A31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. Epilepsia. 2014;55(4):496–506. |
dc.relation.references | Khosama H, Budikayanti A, Khor AHP, Lim KS, Ng CC, Mansyur IG, et al. HLA-B*1502 and carbamazepine induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Indonesia. Neurol Asia. 2017;22(2):113–6. |
dc.relation.references | He N, Min FL, Shi YW, Guo J, Liu XR, Li BM, et al. Cutaneous reactions induced by oxcarbazepine in Southern Han Chinese: Incidence, features, risk factors and relation to HLA-B alleles. Seizure. 2012;21(8):614–8. |
dc.relation.references | Liu Y, Yu Y, Nie X, Zhao L, Wang X. oxcarbazepine-induced cutaneous adverse reaction : a meta-analysis. Pharmacogenomics, 2018; 10.2217/pgs-2017-0189 |
dc.relation.references | Büyüköztürk, S, Keik, C, Gökyiğit, F et al. Cutaneous drug reactions to antiepileptic drugs and relation with HLA alleles in the Turkish population. Eur Ann AllErgy Clin immunol, 2018;36–41. |
dc.relation.references | Paez HA, Siabato AR. Reacciones cutáneas severas secundarias al uso de Lamotrigina Acta Neurol Colomb. 2014;30(1):128–33. |
dc.relation.references | Lin C, Chao WHP, Hsiao WCF. Temporal trends and patterns in carbamazepine use , related severe cutaneous adverse reactions , and HLA ‐ B * 15 : 02 screening : A nationwide study. Epilepsia. 2018;(August):1–15. |
dc.relation.references | Mushiroda T, Takahashi Y, Onuma T et al. Association of HLA-A*31:01 Screening With the Incidence of Carbamazepine-Induced Cutaneous Adverse Reactions in a Japanese Population. JAMA Neurology 2018; doi:10.1001/jamaneurol.2018.0278 |
dc.relation.references | Plumpton CO, Yip VLM, Alfirevic A, Marson AG, Pirmohamed M, Hughes D a. Cost-effectiveness of screening for HLA-A*31:01 prior to initiation of carbamazepine in epilepsy. Epilepsia. 2015;56(4):556–63. |
dc.relation.references | Avila Portillo, Luz Mabel, Carmona, Alejandra, Franco, Leidy, Briceño Ignacio, Casas MC. Bajo polimorfismo en el sistema de antígenos de leucocitos humanos en población mestiza colombiana. UnivMed Bogotá (Colombia). 2010;51(4):359–70. |
dc.relation.references | Liew D. Real-world cost-effectiveness of pharmacogenetic screening for epilepsy treatment. American Academy of Neurology. 2016; 86:1–10. |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |
dc.subject.proposal | Anticonvulsivantes |
dc.subject.proposal | Anticonvulsivants |
dc.subject.proposal | Child |
dc.subject.proposal | Niño |
dc.subject.proposal | Drug-Related Side Effects and Adverse Reactions |
dc.subject.proposal | Efectos Secundarios y Reacciones Adversas Relacionados con Medicamentos |
dc.subject.proposal | HLA Antigens |
dc.subject.proposal | Antígenos HLA |
dc.subject.proposal | Contraindications, Drug |
dc.subject.proposal | Contraindicaciones de los medicamentos |
dc.type.coar | http://purl.org/coar/resource_type/c_1843 |
dc.type.coarversion | http://purl.org/coar/version/c_ab4af688f83e57aa |
dc.type.content | Text |
oaire.accessrights | http://purl.org/coar/access_right/c_abf2 |
Archivos en el documento
Este documento aparece en la(s) siguiente(s) colección(ones)
![Atribución-NoComercial-SinDerivadas 4.0 Internacional](/themes/Mirage2//images/creativecommons/cc-generic.png)